Background As the novel SARS-CoV-2 pandemic occurred, no specific treatment was yet
available. Inflammatory response secondary to viral infection might be the driver of severe …

OBJECTIVE: A substantial number of patients with coronavirus disease-2019 (COVID-19)
demonstrate severe infection. Cytokine storm is an underlying condition that worsens clinical …

tocilizumab in the treatment of systemic inflammatory response in a patient with CoVID-19 (clinical
case) | Avdoshina | Journal Infectology Journal Infectology Žurnal infektologii eng | рус User …

Background Tocilizumab has been proposed as a treatment for the new disease COVID-19,
however, there is not enough scientific evidence to support this treatment. The objective of …

Objective: This study aimed to assess the role of Tocilizumab therapy (TCZ) in terms of ICU
admission and mortality rate of critically ill patients with severe COVID-19 pneumonia …

ABSTRACT BACKGROUND: Coronavirus disease 2019 (COVID-19) can cause cytokine
release syndrome (CRS), which leads to high mortality rates. Tocilizumab suppresses CRS …

Interleukin‐6 (IL‐6)–mediated hyperinflammation may contribute to the mortality of
coronavirus disease 2019 (COVID‐19). The IL‐6 receptor–blocking monoclonal antibody …

Abstract Introduction: Tocilizumab (TCZ), a humanized monoclonal antibody directed
against interleukin-6 (IL-6) receptors, has been tried in various studies as a Covid-19 …

COVID-19 is a public health emergency of international concern with millions confirmed
cases globally including in Indonesia with more than two hundred thousand confirmed …

Abstract Background Coronavirus disease 2019 (Covid-19) is associated with immune
dysregulation and hyperinflammation, including elevated interleukin-6 levels. The use of …